Movicol Plain Sachet

Macrogol 3350, the active ingredient in Movicol Plain Sachet, is an osmotic laxative presented as an oral powder for solution (sachet) for oral use. It is indicated for the relief of constipation in adults and children when dietary measures are insufficient and is commonly prescribed in clinical practice.

GNH USA supplies Movicol Plain Sachet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict quality standards and provides reliable logistics for global distribution.

Movicol Plain Sachet, containing macrogol 3350, is used to treat conditions related to impaired bowel motility and hard stool formation. - Constipation: softens stool and facilitates bowel movements. - Opioid‑induced constipation: provides osmotic effect to relieve constipation associated with opioid therapy. - Chronic idiopathic constipation: helps maintain regular bowel function in long‑term constipation.

Common Side Effects: - Abdominal bloating: feeling of fullness or swelling in the abdomen. - Flatulence: increased intestinal gas. - Nausea: mild discomfort or urge to vomit. - Diarrhoea: loose, watery stools.

Serious or Rare Side Effects: - Severe electrolyte imbalance: abnormal sodium or potassium levels. - Severe abdominal pain: intense, persistent pain. - Allergic reaction: rash, itching, swelling, or angioedema. - Dehydration: excessive loss of body fluids.

Precautions should be observed when using Movicol Plain Sachet. - Assess renal function: adjust use in patients with severe renal impairment. - Monitor electrolytes: prolonged use may affect sodium or potassium levels. - Avoid in intestinal obstruction: risk of perforation. - Use with caution in elderly: higher susceptibility to dehydration. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Potential drug interactions need consideration. Major Interactions (Avoid): - Concurrent use with other osmotic laxatives: may cause severe electrolyte disturbances. - Co‑administration with high‑dose potassium supplements: risk of hyperkalaemia. Moderate Interactions (Monitor Closely): - Antacids containing magnesium: may reduce laxative effectiveness. - Diuretics: monitor electrolyte status during combined therapy. - Lithium: increased risk of lithium toxicity due to altered renal clearance.